Information Provided By:
News For DOC From the Last 2 Days
DOC
Apr 26, 2024 | 13:03 EDT
As previously reported, Exane BNP Paribas upgraded Healthpeak Properties to Outperform from Neutral with a price target of $21, up from $19, after the company boosted its FY24 adjusted funds from operations, or AFFO, per share forecast. While acknowledging that conditions remain challenging for life science given the large amount of new supply, the analyst believes that the current price of shares is "more than adequately pricing in this uncertainty."